vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $13.8M, roughly 1.5× CB Financial Services, Inc.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs 6.9%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $-2.0M). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs 1.2%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CBFV vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $20.4M |
| Net Profit | — | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 38.1% | -18.0% |
| Net Margin | — | -20.4% |
| Revenue YoY | 19.9% | 6.9% |
| Net Profit YoY | — | 64.9% |
| EPS (diluted) | $0.90 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $20.4M | ||
| Q3 25 | $2.4M | $19.9M | ||
| Q2 25 | $13.5M | $19.6M | ||
| Q1 25 | $12.1M | $17.5M | ||
| Q4 24 | $13.2M | $19.1M | ||
| Q3 24 | $12.7M | $20.2M | ||
| Q2 24 | $12.2M | $21.4M | ||
| Q1 24 | $13.5M | $19.3M |
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $-5.7M | $-8.2M | ||
| Q2 25 | $3.9M | $-11.9M | ||
| Q1 25 | $1.9M | $-14.2M | ||
| Q4 24 | — | $-11.8M | ||
| Q3 24 | $3.2M | $-11.1M | ||
| Q2 24 | $2.6M | $-12.3M | ||
| Q1 24 | $4.2M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 38.1% | -18.0% | ||
| Q3 25 | -289.8% | -39.7% | ||
| Q2 25 | 35.0% | -59.6% | ||
| Q1 25 | 19.3% | -79.2% | ||
| Q4 24 | 23.1% | -62.5% | ||
| Q3 24 | 31.2% | -55.7% | ||
| Q2 24 | 26.4% | -59.2% | ||
| Q1 24 | 37.9% | -76.4% |
| Q4 25 | — | -20.4% | ||
| Q3 25 | -235.2% | -41.0% | ||
| Q2 25 | 29.3% | -61.0% | ||
| Q1 25 | 15.8% | -80.8% | ||
| Q4 24 | — | -62.1% | ||
| Q3 24 | 25.3% | -54.9% | ||
| Q2 24 | 21.8% | -57.7% | ||
| Q1 24 | 31.1% | -84.4% |
| Q4 25 | $0.90 | $-0.07 | ||
| Q3 25 | $-1.07 | $-0.16 | ||
| Q2 25 | $0.74 | $-0.23 | ||
| Q1 25 | $0.35 | $-0.28 | ||
| Q4 24 | $0.45 | $-0.23 | ||
| Q3 24 | $0.60 | $-0.22 | ||
| Q2 24 | $0.51 | $-0.25 | ||
| Q1 24 | $0.82 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $157.5M | $63.9M |
| Total Assets | $1.5B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $92.0M | ||
| Q3 25 | $55.9M | $92.4M | ||
| Q2 25 | $64.5M | $101.5M | ||
| Q1 25 | $61.3M | $108.8M | ||
| Q4 24 | $49.6M | $120.4M | ||
| Q3 24 | $147.3M | $118.6M | ||
| Q2 24 | $142.6M | $118.2M | ||
| Q1 24 | $73.7M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $157.5M | $63.9M | ||
| Q3 25 | $152.5M | $64.3M | ||
| Q2 25 | $148.4M | $70.0M | ||
| Q1 25 | $148.3M | $77.6M | ||
| Q4 24 | $147.4M | $87.5M | ||
| Q3 24 | $149.1M | $95.0M | ||
| Q2 24 | $142.9M | $101.6M | ||
| Q1 24 | $141.6M | $109.2M |
| Q4 25 | $1.5B | $115.3M | ||
| Q3 25 | $1.5B | $116.3M | ||
| Q2 25 | $1.5B | $122.0M | ||
| Q1 25 | $1.5B | $129.7M | ||
| Q4 24 | $1.5B | $142.8M | ||
| Q3 24 | $1.6B | $143.6M | ||
| Q2 24 | $1.6B | $149.7M | ||
| Q1 24 | $1.5B | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $-1.8M |
| Free Cash FlowOCF − Capex | $17.2M | $-2.0M |
| FCF MarginFCF / Revenue | 124.1% | -9.7% |
| Capex IntensityCapex / Revenue | 4.7% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $-1.8M | ||
| Q3 25 | $4.6M | $-8.7M | ||
| Q2 25 | $4.1M | $-7.5M | ||
| Q1 25 | $4.0M | $-11.6M | ||
| Q4 24 | $6.8M | $-3.5M | ||
| Q3 24 | $3.1M | $362.0K | ||
| Q2 24 | $-1.2M | $-9.5M | ||
| Q1 24 | $3.3M | $-9.8M |
| Q4 25 | $17.2M | $-2.0M | ||
| Q3 25 | $4.5M | $-8.9M | ||
| Q2 25 | $3.9M | $-7.8M | ||
| Q1 25 | $3.9M | — | ||
| Q4 24 | $3.4M | $-3.6M | ||
| Q3 24 | $2.2M | $311.0K | ||
| Q2 24 | $-2.4M | $-9.5M | ||
| Q1 24 | $2.3M | $-9.9M |
| Q4 25 | 124.1% | -9.7% | ||
| Q3 25 | 186.5% | -44.7% | ||
| Q2 25 | 28.8% | -39.6% | ||
| Q1 25 | 32.5% | — | ||
| Q4 24 | 26.0% | -18.9% | ||
| Q3 24 | 17.4% | 1.5% | ||
| Q2 24 | -19.6% | -44.7% | ||
| Q1 24 | 17.0% | -51.4% |
| Q4 25 | 4.7% | 0.8% | ||
| Q3 25 | 4.3% | 0.9% | ||
| Q2 25 | 1.9% | 1.1% | ||
| Q1 25 | 0.8% | 0.0% | ||
| Q4 24 | 25.1% | 0.7% | ||
| Q3 24 | 6.7% | 0.3% | ||
| Q2 24 | 10.0% | 0.4% | ||
| Q1 24 | 7.2% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
